Good news for Novo in fight against diabetes rivals
New data from a study with Novo Nordisk’s diabetes drug, Tresiba, shows it improves the life quality of patients compared with the world’s best selling diabetes drug. Meanwhile, a separate real-world study confirms Victoza’s superiority over two other rival drugs.
by Stefan Singh Kailay
The Danish diabetes giant, Novo Nordisk, seems to have gained an edge in the clinical race with Sanofi on the market for long-acting insulins.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
